H5N1 VN04-9Mouse anti-Virus, Clone: 7A11, Rockland™

Description

• Store vial at -20°C prior to opening
• Aliquot contents and freeze at -20°C or below for extended storage
• Avoid cycles of freezing and thawing
• Centrifuge product if not completely clear after standing at room temperature
• This product is stable for several weeks at 4°C as an undiluted liquid
• Dilute only prior to immediate use
• Specific for H5 hemagglutinin (HA) protein of influenza A virus [strain A/Vietnam/1203/04 (H5N1)]
• VN04-9 monoclonal antibody did not cross-react with influenza viruses of other HA subtypes
• This monoclonal antibody reacted with H5N1 influenza viruses representatives of different clades and subclades of the H5 HA subtype
• Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA
• In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States
• The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic
• Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins
• The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release
• These proteins also elicit immune responses that prevent infection or independently reduce viral replication
• The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin
• The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.